Skip to main content
Home
 
 
 
MENU
Home
Janssen’s COVID-19 Vaccine Status >

Janssen Global Main Menu

  • Our Company
    • About Us
    • Contact Us
    • Grants & Giving
    • News Center
    • Our Leaders
    • Patient Safety information
    • Products
    • Sustainability
    • Transparency
    • VISIT JANSSEN IN YOUR COUNTRY
  • Our Focus
    • Therapeutic Areas
    • Cardiovascular, Metabolism and Retina
    • Immunology
    • Infectious Diseases & Vaccines
    • Neuroscience
    • Oncology
    • Pulmonary Hypertension
    • Patient Engagement
  • Our Science
    • Our Response to COVID-19
    • Clinical Trials
    • Compassionate Use & Pre-Approval Access
    • R&D Data Science
    • Janssen Global Trial Finder
    • World Without Disease Accelerator
    • Janssen Clinical Innovation
    • Precision Medicine & Janssen Diagnostics

Our Stories List

Making a Splash for Disease Awareness
Global_Trial_Finder
Making a Splash for Disease Awareness
Looking Under the Hood for Green Chemistry Solutions
Global_Trial_Finder
Looking Under the Hood for Green Chemistry Solutions
  • Return to home

Global Trial Finder

  • text size

My Saved Trials

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Last Updated   April 30, 2025

Want to learn how to participate in this trial?

90009530LYM1001

OVERVIEW

  • Sexes Eligible for Study
    all
  • Age
    18+ years
  • Phase
    phase 1
    1
  • Sites
    15 Sites
  • Status
    Recruiting

SUMMARY

The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are:

* can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients.
* will JNJ-90009530 help patients achieve a response and for how long?

CONDITIONS

  • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

ELIGIBILITY


Key Inclusion Criteria

* Participant must be greater than or equal to (>=) 18 years of age, at the time of signing informed consent
* All participants must have relapsed or refractory disease for each histologic subtype

* Mature aggressive large B cell NHL and Follicular Lymphoma Grade 3b: Participants must have >= 2 lines of systemic therapy or >=1 line of systemic therapy in case of participants ineligible for high-dose chemotherapy and autologous Hematopoietic stem cell transplantation (HSCT). Participants also must have had exposure to an anthracycline and an anti-CD20 targeted agent
* Follicular lymphoma Grade 1-3a and Marginal Zone Lymphoma: Participants must have >=2 prior lines of anti-neoplastic systemic therapy. Participants also must have prior exposure to an anti-CD20 monoclonal antibody
* Tumor must be cluster of differentiation (CD) 20 positive
* Measurable disease as defined by Lugano 2014 classification
* Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1

Key Exclusion Criteria

* Diagnosis of Human herpes virus (HHV) 8-positive Diffuse large B Cell lymphoma (DLBCL)
* Prior allogeneic Hematopoietic stem cell transplantation (HSCT)
* Autologous stem cell transplant within 12 weeks of chimeric antigen receptor (CAR) T cell infusion
* Uncontrolled active infections
* History of deep vein thrombosis or pulmonary embolism within six months of infusion (except for line associated deep vein thrombosis [DVT])
* History of stroke, unstable angina, myocardial infarction, congestive heart failure ( New York Heart Association [NYHA] Class III or IV), severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of screening
* History of a seizure disorder, dementia, cerebellar disease or neurodegenerative disorder
* Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system
* Active central nervous system (CNS) involvement by malignancy
* Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)


Key Inclusion Criteria

* Participant must be greater than or equal to (>=) 18 years of age, at the time of signing informed consent
* All participants must have relapsed or refractory disease for each histologic subtype

* Mature aggressive large B cell NHL and Follicular

More...

DETAILS

LOCATIONS

Locations in:
United States, Australia, Israel, United Kingdom
Country (4) City or Province (15) Status
United States Iowa City University of Iowa Hospital
RECRUITING
United States Lexington University of Kentucky
RECRUITING
United States New Brunswick Rutgers University
RECRUITING
United States Cleveland University Hospitals Cleveland Medical Center
RECRUITING
United States Philadelphia University of Pennsylvania
RECRUITING
United States Houston MD Anderson Cancer Center
RECRUITING
Australia Camperdown Royal Prince Alfred Hospital
RECRUITING
Australia Clayton Monash Medical Centre
RECRUITING
Australia Heidelberg Austin Hospital
RECRUITING
Australia Herston Royal Brisbane and Women's Hospital
RECRUITING
Australia Westmead Westmead Hospital
RECRUITING
Israel Jerusalem Hadassah Medical Center
RECRUITING
Israel Ramat Gan Sheba Medical Center
RECRUITING
United Kingdom London University College London Hospitals
RECRUITING
United States Rochester Mayo Clinic Rochester
RECRUITING
Show More
Geo Locations

41.66113, -91.53017

37.98869, -84.47772

40.48622, -74.45182

41.4995, -81.69541

39.95233, -75.16379

29.76328, -95.36327

-33.88965, 151.17642

-37.91667, 145.11667

-37.75, 145.06667

-27.44453, 153.01852

-33.80383, 150.98768

31.76904, 35.21633

32.08227, 34.81065

51.50853, -0.12574

44.02163, -92.4699

x
50

Indicates 50+ sites in this region: click to zoom in.

10

Indicates 10+ sites in this region: click to zoom in.

5

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Interested in participating?

×

Confirm


If you are interested in this clinical trial, we will use your email address to respond to your questions and fulfill your requests as necessary for our legitimate interest and possibly to comply with our legal obligations relating to pharmacovigilance. Please read our Privacy Policy.

Footer

  • PRIVACY POLICY
  • LEGAL NOTICE
  • COOKIE POLICY
  • COOKIE SETTINGS
  • CAREERS
  • NEWS CENTER
  • DO NOT SELL MY PERSONAL INFORMATION

Footer Social

Find Janssen Global on:

twitter youtube linkedin

Janssen Global Policy text

©Johnson & Johnson Innovative Medicine. All Rights Reserved. This website is hosted and operated by Johnson & Johnson Innovative Medicine, which is solely responsible for its content. This website is intended for a global audience.